global provider of customized laboratory and research services

KRAS

KRAS Mutation Detection Assays

We provide KRAS mutation detection assay on paraffin block tissue samples (standard material used in the post-operative analysis of tumour samples).

The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers.

Candidates

If the candidate meets the following criteria, KRAS Mutation Detection test could be available:

  • Patient has been diagnosed with metastatic colorectal cancer.
  • Patient has failed on fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
  • Patient will be prescribed Vectibix™ or Erbitux® if the results of the KRAS test indicate the tumor is non-mutated (wild-type) KRAS.

Other Indications

Other indications when KRAS Mutation Detection would be helpful include:

  • Patients currently treated with Vectibix™ (panitumumab) or Erbitux® (cetuximab) for colorectal cancer (or prior to commencing treatment).
  • Patients with lung cancer under treatment with tyrosine kinase inhibitors such as Iressa™ (AstraZeneca) or Tarceva™ (Roche/OSI Pharmaceuticals).

More Information

For Health Care Practitioners who require more information on Vectibix®, please visit Amgen Canada’s Vectibix.ca website.

General information for patients about KRAS testing is available through Colorectal Cancer Coalition website .

Colon Cancer

KRAS Mutation Detection in Treatment of Colorectal Cancer

KRAS Mutation Detection Assay

Links

References

KRAS NIPT PGS/PGD BLADDERPREDICT™

KRAS Requisition Forms

These requisition forms are fillable PDFs. You can complete the forms by typing your information in the provided fields, then print a hard copy for faxing. You will not be submitting your information online.